Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation

Pharmaceutical Development and Technology

Volumn 21, Issue 8, 2016, Pages 951-960

  Garg, Tarun ^a   Goyal, Amit K ^a   Rath, Goutam ^a   Murthy, R S R ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Alginate; in vitro and in vivo studies; pulmonary drug delivery; spray dried particle; tuberculosis

Indexed keywords

ALGINIC ACID; ISONIAZID; RIFAMPICIN; DELAYED RELEASE FORMULATION; GLUCURONIC ACID; HEXURONIC ACID; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; ENCAPSULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SPRAY DRYING; SUSTAINED DRUG RELEASE; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MEDICINAL CHEMISTRY; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PARTICLE SIZE; PROCEDURES; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ALGINATES; ANIMALS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PARTICLE SIZE; RIFAMPIN; TUBERCULOSIS;

EID: 84940736587     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2015.1081613     Document Type: Article

References (43)

1. Pham DD, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm 2015;478:517–529
2. Singh H, Jindal S, Singh M, et al. Nano-formulation of rifampicin with enhanced bioavailability:development, characterization and in-vivo safety. Int J Pharm 2015;485:138–151
3. Sukhithasri V, Vinod V, Varma S, Biswas R. Mycobacterium tuberculosis treatment modalities and recent insights. Curr Drug Deliv 2014;11:744–752
4. Chan JG, Tyne AS, Pang A, et al. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. Int J Antimicrob Agents 2015;45:319–323
5. Das S, Tucker I, Stewart P. Inhaled dry powder formulations for treating tuberculosis. Curr Drug Deliv 2015;12:26–39
6. Kaur M, Garg T, Narang RK. A review of emerging trends in the treatment of tuberculosis. Artif Cells Nanomed Biotechnol 2014. [Epub ahead of print]. doi:10.3109/21691401.2014.962745
7. Pourshahab PS, Gilani K, Moazeni E, et al. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsul 2011;28:605–613
8. Chaubey P, Mishra B. Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis. Carbohydr Polym 2014;101:1101–1108
9. Rastogi R, Sultana Y, Ali A, Aqil M. Particulate and vesicular drug carriers in the management of tuberculosis. Curr Drug Deliv 2006;3:121–128
10. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst 2014;31:49–88
11. Ahmad Z, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26:298–303
12. Lee KY, Mooney DJ. Alginate:properties and biomedical applications. Prog Polym Sci 2012;37:106–126
13. Sayag J, Meaume S, Bohbot S. Healing properties of calcium alginate dressings. J Wound Care 1996;5:357–362
14. Ahmad Z, Sharma S, GK K. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine 2007;3:239–243
15. Bhutani H, Singh S, Jindal KC. Drug-drug interaction studies on first-line anti-tuberculosis drugs. Pharm Dev Technol 2005;10:517–524
16. Agrawal S, Kaur KJ, Singh I, et al. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2002;233:169–177
17. Avachat AM, Bhise SB. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin. Pharm Dev Technol 2011;16:127–136
18. Koch K, Dew B, Corcoran TE, et al. Surface tension gradient driven spreading on aqueous mucin solutions:a possible route to enhanced pulmonary drug delivery. Mol Pharm 2011;8:387–394
19. Bohr A, Ruge CA, Beck-Broichsitter M. Preparation of nanoscale pulmonary drug delivery formulations by spray drying. Adv Exp Med Biol 2014;811:183–206
20. Beck-Broichsitter M, Schweiger C, Schmehl T, et al. Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. J Control Release 2012;158:329–335
21. Yang WW, Pierstorff E. Reservoir-based polymer drug delivery systems. J Lab Autom 2012;17:50–58
22. Kaur R, Garg T, Malik B, et al. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv 2014. [Epub ahead of print]. doi:10.3109/10717544.2014.920428
23. Yousefi S, Emam-Djomeh Z, Mousavi SM. Effect of carrier type and spray drying on the physicochemical properties of powdered and reconstituted pomegranate juice (Punica Granatum L.). J Food Sci Technol 2011;48:677–684
24. Son YJ, Worth Longest P, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application:effect of spray drying process conditions on aerosol performance. Int J Pharm 2013;443:137–145
25. Badawy SI, Shah KR, Surapaneni MS, et al. Effect of spray-dried mannitol on the performance of microcrystalline cellulose-based wet granulated tablet formulation. Pharm Dev Technol 2010;15:339–345
26. Sou T, Orlando L, McIntosh MP, et al. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery:a design of experiment approach. Int J Pharm 2011;421:220–229
27. Nekkanti V, Muniyappan T, Karatgi P, et al. Spray-drying process optimization for manufacture of drug-cyclodextrin complex powder using design of experiments. Drug Dev Ind Pharm 2009;35:1219–1229
28. Kaur R, Garg T, Das Gupta U, et al. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif Cells Nanomed Biotechnol 2014. [Epub ahead of print]. doi:10.3109/21691401.2014.930747
29. Saraogi GK, Gupta P, Gupta UD, et al. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 2010;385:143–149
30. Krasucka DM, Kos K, Cybulski WA, et al. Karl Fisher determination of residual moisture in veterinary vaccines–practical implementation in market monitoring. Acta Pol Pharm 2012;69:1364–1367
31. Learoyd TP, Burrows JL, French E, Seville PC. Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm 2008;68:224–234
32. Ezzati Nazhad Dolatabadi J, Hamishehkar H, Valizadeh H. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles:solid-state characterization and aerosol dispersion performance. Drug Dev Ind Pharm 2015;41:1431–1437
33. Ortiz M, Jornada DS, Pohlmann AR, Guterres SS. Development of novel chitosan microcapsules for pulmonary delivery of dapsone:characterization, aerosol performance, and in vivo toxicity evaluation. AAPS PharmSciTech 2015. [Epub ahead of print]. doi:10.1208/s12249-015-0283-3
34. Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech 2008;9:755–761
35. Tiruveedhula VV, Witzigmann CM, Verma R, et al. Design and synthesis of novel antimicrobials with activity against Gram-positive bacteria and mycobacterial species, including M. tuberculosis. Bioorg Med Chem 2013;21:7830–7840
36. Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011;19:468–474
37. Alexander BD, Winkler TP, Shi S, et al. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. Pharm Dev Technol 2011;16:577–582
38. Bhatt NB, Barau C, Amin A, et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother 2014;58:3182–3190
39. Tian G, Longest PW, Li X, Hindle M. Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm Drug Deliv 2013;26:248–265
40. Saini D, Biris AS, Srirama PK, Mazumder MK. Particle size and charge distribution analysis of pharmaceutical aerosols generated by inhalers. Pharm Dev Technol 2007;12:35–41
41. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008;25:999–1022
42. Lechuga-Ballesteros D, Charan C, Stults CL, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 2008;97:287–302
43. Nahar K, Gupta N, Gauvin R, et al. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci 2013;49:805–818